Usynova Pharmaceuticals

Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) concerning its pipeline candidate, UA022. UA022 is a small-molecule drug targeting the KRASG12D mutation, currently in the pre-clinical stages of development. Terms of the Agreement and FinancialsUnder the agreement, AstraZeneca (AZ) will secure…